Short- and long-term effects of whole-body photobiomodulation on pain, functionality, tissue quality, central sensitisation and psychological factors in a population suffering from fibromyalgia: protocol for a triple-blinded randomised clinical trial
Metadatos
Mostrar el registro completo del ítemEditorial
SAGE
Materia
Chronic pain Elasticity imaging techniques Fibromyalgia Pain perception Photobiomodulation therapy Pressure algometry Pressure pain threshold Psychology Ultrasonography
Fecha
2022-02-21Referencia bibliográfica
Navarro-Ledesma, S... [et al.] (2022). Short- and long-term effects of whole-body photobiomodulation on pain, functionality, tissue quality, central sensitisation and psychological factors in a population suffering from fibromyalgia: protocol for a triple-blinded randomised clinical trial. Therapeutic Advances in Chronic Disease. [https://doi.org/10.1177/20406223221078095]
Patrocinador
THOR PhotomedicineResumen
Background: The development of an integral and global treatment to improve the quality of life
in those with fibromyalgia syndrome (FMS) is challenging. The aim of this study is to investigate
the impact of whole-body photobiomodulation (PBM) on pain perception, functionality, quality of
soft tissue, central sensitisation and psychological factors in patients suffering with FMS.
Methods: This study is a randomised, placebo-controlled clinical trial. A total of 44
participants will be recruited in a private care practice and randomised to receive either a
whole-body PBM therapy programme or placebo in the same care centre. The parameters of
the PBM programme are as follows: wavelengths of red and near-infrared LEDs 50:50 ratio
with 660–850 nanometers; fluence of 25.2 J/cm2; treatment time of 1200 s and a total power
emitted of 967 W. Treatment sessions will be 3 times weekly for a period of 4 weeks, totalling
12 treatment sessions. Primary outcome will be pain (Numeric Pain Rating Scale; Widespread
Pain Index; Symptom Severity Score). Secondary outcomes will be functionality (Fibromyalgia
Impact Questionnaire; the Leisure Time Physical Activity Instrument), quality of soft tissue
(elastography), central sensitisation (pain pressure threshold and the Autonomic Symptom
Profile) and psychological factors (Pain Catastrophising scale, Tampa Scale, Self-Efficacy
questionnaire). Assessments will be at baseline (T1), after session 6 (T2), after treatment (T3)
and 2 weeks (T4), 3 (T5) and 6 (T6) month follow-up.
Discussion: PBM therapy has been shown to reduce pain and inflammation and to increase
the rate of tissue repair for a wide range of conditions, but its potential use as a whole-body
treatment in FM is yet to be explored. This trial will investigate whether whole-body PBM
therapy is effective at reducing pain intensity, improving functionality, quality of soft tissue,
central sensitisation symptoms and psychological measurements. Furthermore, 3- and
6-month follow-up will investigate long-term efficacy of this treatment.